Get started
Author

Vanessa S. Rodrik-Outmezguine

Observed names: Rodrik-Outmezguine, Vanessa, V Rodrik-Outmezguine, V. Rodrik-Outmezguine, V.S. Rodrik-Outmezguine, Vanessa Rodrik, Vanessa Rodrik-Outmezguine, Vanessa Rodrik-outmezguine
Observed institutions: AstraZeneca (United Kingdom), Novartis (Switzerland), BC Cancer Agency, Université Libre de Bruxelles, Memorial Sloan Kettering Cancer Center, Eli Lilly (United States), City University of New York, Peter MacCallum Cancer Centre, Cancer Research UK, Institut Jules Bordet, Yale University, Breast International Group, Hunter College, Massachusetts General Hospital, Novartis (United States), Kyoto University Hospital, University Hospital Ulm, Fondazione IRCCS Istituto Nazionale dei Tumori, Weill Cornell Medicine, Bayer (Germany), Ludwig-Maximilians-Universität München
ORCID: 0009-0006-3219-1181
Observed ORCIDs: 0009-0006-3219-1181, 0000-0002-3024-4490
OpenAlex ID: A5081318256
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
2011 · Sarat Chandarlapaty, Ayana Sawai, et al. · Cancer Cell · 965
PDF
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
2017 · Zhan Yao, Rona Yaeger, et al. · Nature · 561
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
2016 · Vanessa S. Rodrik-Outmezguine, Masanori Okaniwa, et al. · Nature · 474
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
2011 · Vanessa S. Rodrik-Outmezguine, Sarat Chandarlapaty, et al. · Cancer Discovery · 441
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer
2013 · Moshe Elkabets, Sadhna Vora, et al. · Science Translational Medicine · 331
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
2014 · Sarit Schwartz, John Wongvipat, et al. · Cancer Cell · 247
PDF
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling
2014 · Marie Will, Alice Can Ran Qin, et al. · Cancer Discovery · 195
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
2019 · Aleix Prat, Tomás Pascual, et al. · JNCI Journal of the National Cancer Institute · 175
Phospholipase D Couples Survival and Migration Signals in Stress Response of Human Cancer Cells
2006 · Yang Zheng, Vanessa Rodrik, et al. · Journal of Biological Chemistry · 136
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
2019 · Françoise Rothé, Maria Joao Silva, et al. · Clinical Cancer Research · 128
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
2011 · Paige Yellen, Mahesh Saqcena, et al. · Cell Cycle · 117
PDF
Alternative phospholipase D/mTOR survival signal in human breast cancer cells
2004 · Yuhong Chen, Vanessa Rodrik, et al. · Oncogene · 116
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
2017 · P. Nuciforo, T. Pascual, et al. · Annals of Oncology · 111
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
2016 · Jianing Xu, Can G. Pham, et al. · Journal of Clinical Investigation · 97
PDF
Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma
2009 · Kathryn E. O'Reilly, Melanie Warycha, et al. · Clinical Cancer Research · 70
PDF
Survival Signals Generated by Estrogen and Phospholipase D in MCF-7 Breast Cancer Cells Are Dependent on Myc
2005 · Vanessa Rodrik, Yang Zheng, et al. · Molecular and Cellular Biology · 61
PDF
mTOR-dependent Suppression of Protein Phosphatase 2A Is Critical for Phospholipase D Survival Signals in Human Breast Cancer Cells
2005 · Li Hui, Vanessa Rodrik, et al. · Journal of Biological Chemistry · 57
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
2024 · Komal L. Jhaveri, Elgene Lim, et al. · Journal of Clinical Oncology · 49
PDF
Canakinumab with and Without Pembrolizumab in Patients with Resectable Non-Small-Cell Lung Cancer: CANOPY-N Study Design
2021 · Pilar Garrido, Jean-Louis Pujol, et al. · Future Oncology · 49
PDF
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses
2023 · Rohan Diwanji, Neil A. O'Brien, et al. · Cancer Immunology Research · 41
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
2024 · Sherene Loi, Stephen R. D. Johnston, et al. · Journal of Clinical Oncology · 40
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer
2018 · Kristina Golfmann, Lydia Meder, et al. · Oncogene · 39
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2024 · Shripad V. Bhagwat, Cecilia Mur, et al. · Cancer Research · 29
PDF
Myc stabilization in response to estrogen and phospholipase D in MCF‐7 breast cancer cells
2006 · Vanessa Rodrik, Evan Gomes, et al. · FEBS Letters · 28
PDF
Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
2024 · Nicholas Turner, Jorge Reis-Filho, et al. · Cancer Research · 13
Works count: 157
Citation count: 4,628
H-index: 24
I10-index: 27
Year
Topic
Type